Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Groen

Showing results (431-440 of 564) with videos related to

Pageof 57
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2010
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerJoline S W Lind, Anne-Marie C Dingemans, Harry J M Groen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2020
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy RegistryH J M Smit, J Aerts, M van den Heuvel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 12, 2013
PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patientsVikram R Bollineni, Gerald S M A Kerner, Jan Pruim, et al.
The European Respiratory Journal|July 13, 2013
Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trialNanda Horeweg, Carlijn M van der Aalst, Rozemarijn Vliegenthart, et al.
The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†A-M C Dingemans, H J M Groen, G J M Herder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumorsJ A Gietema, R Hoekstra, F Y F L de Vos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|July 22, 2014
Polygenic scores associated with educational attainment in adults predict educational achievement and ADHD symptoms in childrenEveline L de Zeeuw, Catharina E M van Beijsterveldt, Tina J Glasner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialF Barlesi, A Scherpereel, V Gorbunova, et al.
Pageof 57

Showing results (431-440 of 564) with videos related to

Sort By:
Pageof 57
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2010
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerJoline S W Lind, Anne-Marie C Dingemans, Harry J M Groen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2020
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy RegistryH J M Smit, J Aerts, M van den Heuvel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 12, 2013
PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patientsVikram R Bollineni, Gerald S M A Kerner, Jan Pruim, et al.
The European Respiratory Journal|July 13, 2013
Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trialNanda Horeweg, Carlijn M van der Aalst, Rozemarijn Vliegenthart, et al.
The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†A-M C Dingemans, H J M Groen, G J M Herder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumorsJ A Gietema, R Hoekstra, F Y F L de Vos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|July 22, 2014
Polygenic scores associated with educational attainment in adults predict educational achievement and ADHD symptoms in childrenEveline L de Zeeuw, Catharina E M van Beijsterveldt, Tina J Glasner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialF Barlesi, A Scherpereel, V Gorbunova, et al.
Pageof 57